Effects of prednisone and deflazacort on vertebral bone mass.
The effects of a 12-month therapeutic course of two different glucocorticoids, prednisone and deflazacort (an oxazoline derivative of prednisolone), on vertebral and femoral bone was analyzed by dual photon absorptiometry. The data, which reveal a significantly less bone loss with deflazacort (9.7% in 12 months) than with prednisone (21.4% in 12 months), further document the advantage of deflazacort as a glucocorticoid medication in subjects with osteopenic syndromes.
D000893:Anti-Inflammatory Agents / Q000009:adverse effects* / Q000627:therapeutic use; D004311:Double-Blind Method; D006801:Humans; D008903:Minerals / Q000378:metabolism; D010014:Osteolysis / Q000378:metabolism; D011241:Prednisone / Q000009:adverse effects* / Q000627:therapeutic use; D011282:Pregnenediones / Q000009:adverse effects* / Q000627:therapeutic use; D013131:Spine / Q000187:drug effects* / Q000378:metabolism; D013997:Time Factors
D000893:Anti-Inflammatory Agents; D008903:Minerals; D011282:Pregnenediones; C021988:deflazacort; D011241:Prednisone